Seoul St. Mary's Hospital, First to Build Specialized Big Data for Rare and Intractable Blood Cancer 'Dabalgolsujong'

Professor Min Chang-ki (left), Department of Hematology, Seoul St. Mary's Hospital, and Professor Han Seung-hoon, Department of Clinical Pharmacology.

[Asia Economy Reporter Lee Gwan-joo] The Catholic University Seoul St. Mary's Hospital announced on the 4th that it has established the first specialized Korean multiple myeloma data by linking epidemiological big data from the National Health Insurance Service.

The research team led by Professors Min Chang-ki and Park Sung-soo from the Hematology Hospital at Seoul St. Mary's Hospital, along with Professor Han Seung-hoon from the Clinical Pharmacology Department, combined data from 1,881 patients diagnosed with multiple myeloma at Seoul St. Mary's Hospital since 2009 with 15,86 matching health insurance records from 30,353 multiple myeloma patient records in the National Health Insurance Service public data.

Through this 'heterogeneous data' integration, the research team secured high-quality big data by adding long-term follow-up data including patients' epidemiological history held by the National Health Insurance Service, death status, and nationally invested medical costs to the hospital's disease data such as genetic factors, treatment processes, and post-treatment relapse courses.

It is expected that this specialized multiple myeloma data construction will promote disease diagnosis and prediction research based on data and provide customized precision medical services. Professor Min said, “There were limitations in providing patient-tailored treatment suited to domestic conditions using multiple myeloma data accumulated from actual clinical practice at a single medical institution, but through this heterogeneous data integration, we can establish more precise treatment strategies for Korean multiple myeloma patients, which is very promising.”

This research was conducted as part of the Cancer Conquest Promotion Research and Development Project supported by the National Cancer Center's Cancer Conquest Promotion Planning Group.

This content was produced with the assistance of AI translation services.